“Enhancing R&D Productivity and Global Market Access in a Challenging Regulatory and Payor Environment”
- Moderator: Professor Cliff Cramer, Adjunct Professor and Director, Healthcare and Pharmaceutical Management Program, Columbia Business School
- Michael Aberman, MD, VP Strategy & Investor Relations, Regeneron
- Mark J. Alles, Executive Vice President and Chief Commercial Officer, Celgene
- Paul Fonteyne, President and CEO, Boehringer-Ingelheim USA
- Michele Holcomb, PhD, Senior Vice President and Chief Operating Officer of GR&D, Teva Pharmaceuticals
- Portfolio optimization strategies in a resource-constrained environment, including external technology sourcing.
- Examples of effective risk mitigation strategies employed at various stages of a compound’s development and commercialization path.
- Changes in the oncology landscape (development, regulatory, use of biomarkers, payor/reimbursement, etc.), including next generation of novel therapies and vaccines.
- Effective strategies to enhance the value proposition to payors (clinical, economic).
- Emerging markets strategies and profit potential – near-term and longer-term.
- Pros/cons of pharma companies pursuing adjacent areas of business (e.g., consumer health, generics/ biosimilars, animal health, diagnostics, etc.).
Adjunct Professor and Director, Healthcare and Pharmaceutical Management Program
Columbia Business School
Cliff Cramer spent over 25 years as a senior professional in the financial services and healthcare/ pharmaceutical sectors. He was Managing Director at JP Morgan and Merrill Lynch in their global healthcare investment banking groups, and Vice President, Corporate Planning & Development at Merck & Co., Inc., with worldwide responsibilities for strategic planning and business development.
Mr. Cramer’s previous experience includes the co-founding of American Health Capital / VHA Enterprises, Inc., a healthcare/ financial services firm serving the capital needs of multi-hospital systems and other healthcare providers, and investment banking positions with Paine Webber, Inc. and L.F. Rothschild, Unterberg, Towbin, Inc. Mr. Cramer serves as board member (past president) of Big Brothers Big Sisters of Mercer County, NJ.
Mr. Cramer is currently Director of the Healthcare and Pharmaceutical Management Program and Adjunct Professor at Columbia Business School. He teaches two MBA courses: Strategy and Competition in Pharmaceuticals and Biotechnology, and Healthcare Investment and Dealmaking.
Vice President, Strategy and Investor Relations
Regeneron Pharmaceutical, Inc.
Michael Aberman, MD is Vice President, Strategy and Investor Relations of Regeneron Pharmaceutical, Inc. Prior to joining Regeneron in 2010, Dr. Aberman spent six years as a Wall Street research analyst covering the biotechnology industry. Most recently, he was Director and Senior Biotechnology Analyst at Credit Suisse and prior to that, Vice President and Biotech Analyst at Morgan Stanley. Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman received his medical degree from the University of Toronto, completed residency training at New York Presbyterian Hospital, and received an M.B.A. from The Wharton School of Business.
Executive Vice President and Chief Commercial Officer
Mark J. Alles is Executive Vice President and Chief Commercial Officer with responsibility for global commercial operations. He joined Celgene in April 2004 and served as Vice President, Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Prior to joining Celgene, Mark was Vice President for the US Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11 year period with Aventis. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mark started his 25-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He currently serves as a Director for Gilda's Club NYC, a not-for-profit organization helping people with cancer.
President and CEO
Paul R. Fonteyne assumed the role of US Country Managing Director and President and CEO of Boehringer Ingelheim USA Corporation on January 1, 2012.
Prior to assuming his present role he was the US Corporate Senior Vice President, Corporate Division Marketing, Prescription Medicines and led the global marketing strategy supporting Boehringer Ingelheim’s Prescription Medicines Business, based in Ingelheim Germany. In this position, Paul led the global marketing teams that prepared for launches of new medicines worldwide, and managed the entire BI Prescription Medicines portfolio worldwide. Paul was a member of all global governance bodies related to the Prescription Medicines Business of BI.
Paul Fonteyne joined Boehringer Ingelheim Pharmaceuticals Inc. in 2003 as Executive Vice President and Head of Marketing and Sales of BI US. He was a member of the Boehringer Ingelheim Corporation’s Corporate Management Committee and is responsible for the Prescriptions Medicines business in the US.
Prior to joining BI, Paul worked for Merck & Co. and Abbott Laboratories in positions of increasing responsibility in Marketing & Sales.
Born in Brussels, Belgium, Paul was awarded an MS in Chemical Engineering from the University of Brussels in 1985 and an MBA from Carnegie Mellon University in 1987. Paul became a US citizen in 1988.
Currently Paul serves on the Board of Pharmaceutical Research and Manufacturers of America, Washington, D.C. In the past he served as Chairman of the Board of the National Pharmaceutical Council, an industry group focused on demonstrating the value of pharmaceutical products. He is also on the Bio Advisory Board of the Kellogg School of Management (Northwestern University).
Paul resides in Westport, CT with his wife, Nathalie, and three children.
Senior Vice President and Chief Operating Officer of GR&D
Michele Holcomb is the Chief Operating Officer of Teva Global R&D, which encompasses the full range of Teva’s pharmaceutical development, for both the Branded and Generics businesses. Teva Pharmaceuticals is the leading generic pharmaceutical company in the world and among the Top 15 global pharmaceutical companies. Her role includes management of the core operational aspects of R&D, including financials, governance committees, project management, and interfaces among R&D and the rest of Teva’s functions and business units. Michele joined Teva in 2010, as the Vice President of Corporate Strategy, where she focused on issues across Commercial, Business Development, R&D and Operations. Prior to joining Teva, Michele was a Partner in the Global Pharmaceutical Practice at McKinsey & Company where she served many of the Top 10 global Pharmaceutical companies as well as high-growth Biotechs and Mid-Cap pharmaceutical companies. She worked closely with clients on strategic and operational issues, across R&D, Sales & Marketing, Business Development, in both growth and turnaround situations.
Michele is trained as a chemist, with a B.S. from Stanford University, a Ph.D. from the University of California, Berkeley, and experience as a bench chemist at Syntex Pharmaceuticals and Ciba-Geigy. Michele enjoys running, surfing, cooking, and traveling.